Steve - I distribute all of them. TMO, Cepheid, Roche,
Abbott, Siemens, etc...the great thing is that all of the
manufacturers of lab analyzers will be able to offer solutions.
saffer - yes it's a step forward but more are needed. DHR
should catch a nice bid in this type of market. Send me you email
address via private inbox here on the blog. Simply click on
the envelope below one of my posts.
That is a standard lateral flow test. 99% of lateral flow
tests, if you get a negative result and the patient is
"symptomatic" you have to send out to a reference lab for
confirmation (typically takes 3 days to get that confirmation
results back). That test in not Molecular technology.
It is good for a first line of testing but the accuracy of
lateral flow tests for example with Flu A/B is only 50%.
Molecular technology actually incubates the samples strips
the RNA and amplifies it to get an early detection of the
virus, There is a difference in testing
methodologies.
Steve - I distribute all
Separately, the Food and Drug Administration announced on Saturday that ...
Posted by ssaffer on 22nd of Mar 2020 at 11:40 am
Steve - I distribute all of them. TMO, Cepheid, Roche, Abbott, Siemens, etc...the great thing is that all of the manufacturers of lab analyzers will be able to offer solutions.
saffer - yes it's a
Posted by steve on 22nd of Mar 2020 at 11:46 am
saffer - yes it's a step forward but more are needed. DHR should catch a nice bid in this type of market. Send me you email address via private inbox here on the blog. Simply click on the envelope below one of my posts.
That is a standard lateral
Posted by ssaffer on 22nd of Mar 2020 at 11:58 am
That is a standard lateral flow test. 99% of lateral flow tests, if you get a negative result and the patient is "symptomatic" you have to send out to a reference lab for confirmation (typically takes 3 days to get that confirmation results back). That test in not Molecular technology. It is good for a first line of testing but the accuracy of lateral flow tests for example with Flu A/B is only 50%. Molecular technology actually incubates the samples strips the RNA and amplifies it to get an early detection of the virus, There is a difference in testing methodologies.
Yes good for a first
Posted by steve on 22nd of Mar 2020 at 12:01 pm
Yes good for a first line of testing instead of overwhelming the healthcare system. Thanks so very much for your input.